The levels of autoantibodies were lower in patients with acute GVHD history. A total of 5 markers (sIL-2Rα, sBAFF, sCD13, anti-dsDNA antibody, and ANA) in patients with de novo cGVHD (■) were compared with patients with a previous history of acute GVHD (▴) and non-GVHD control (▾).